Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Daily Summary: Hawkish Fed fails to scare the markets (17.09.2026)
Nasdaq 100 Up 1.7%
US Open: Nasdaq, gold and silver surge following... an interest rate hike (17.09.2026)
JB Hunt shares down 13% ๐ US transportation stocks have problems?